![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trubion Pharmaceuticals (MM) | NASDAQ:TRBN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.60 | 0 | 01:00:00 |
Delaware | 52-2385898 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification Number) |
Large
accelerated filer
o
Non-accelerated filer o (Do not check if a smaller reporting company) |
Accelerated filer
þ
Smaller reporting company o |
Amount | ||||||||||||||||
to be | Proposed | Proposed | ||||||||||||||
Title of securities to be | registered | maximum offering | maximum aggregate | Amount of | ||||||||||||
registered | (1) | price per share (3) | offering price | registration fee | ||||||||||||
Common Stock, $0.001 par value, available for issuance under the 2006 Equity Incentive Plan
|
889,609 shares (2) | $6.33 | $5,631,225 | $221.31 | ||||||||||||
Total
|
889,609 shares | $5,631,225 | $221.31 | |||||||||||||
(1) | Pursuant to Rule 416(a) of the Securities Act of 1933, this Registration Statement shall also cover any additional shares of the Registrants common stock that become issuable under the 2006 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrants outstanding shares of common stock. | |
(2) | Represents shares of Common Stock automatically reserved in January 2008 for options that may be granted under the 2006 Equity Incentive Plan. | |
(3) | Offering prices of awards that have not yet been granted as of the date of this Registration Statement are computed in accordance with Rule 457(c) and 457(h) of the Securities Act of 1933, as amended, solely for the purpose of calculating the registration fee based upon the price of $6.33 per share, the average of the high and low prices of the Registrants common stock on May 30, 2008, as reported on the Nasdaq Global Market. |
SIGNATURES | ||||||||
INDEX TO EXHIBITS | ||||||||
EXHIBIT 5.1 | ||||||||
EXHIBIT 23.2 |
TRUBION PHARMACEUTICALS, INC.
|
||||
By: | /s/ PETER A. THOMPSON | |||
Peter A. Thompson, M.D., FACP | ||||
President, Chief Executive Officer and
Chairman of the Board of Directors |
||||
Signature | Title | Date | ||
|
||||
/s/ PETER A. THOMPSON
|
President, Chief Executive Officer, Chairman of the Board and Director (Principal Executive Officer) | June 5, 2008 | ||
|
||||
/s/ MICHELLE G. BURRIS
|
Senior Vice President and Chief
Financial Officer
(Principal Accounting and Financial Officer) |
June 5, 2008 | ||
|
||||
/s/ LEE R. BRETTMAN
|
Director | June 5, 2008 | ||
|
||||
/s/ PATRICK HERON
|
Director | June 5, 2008 | ||
|
||||
/s/ ANDERS D. HOVE
|
Director | June 5, 2008 | ||
|
Signature | Title | Date | ||
/s/ STEVEN GILLIS
|
Director | June 5, 2008 | ||
|
||||
/s/ DAVID A. MANN
|
Director | June 5, 2008 | ||
|
||||
/s/ SAMUEL R. SAKS
|
Director | June 5, 2008 | ||
|
||||
/s/ DAVID SCHNELL
|
Director | June 5, 2008 |
Exhibit | ||||
Number | Description | |||
5.01 |
Opinion of Fenwick & West, LLP
|
|||
23.1 |
Consent of Fenwick & West, LLP (see Exhibit 5.01)
|
|||
23.2 |
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
|
|||
24.1 |
Power of Attorney (included as part of the signature page to this Registration Statement)
|
1 Year Trubion Pharmaceuticals (MM) Chart |
1 Month Trubion Pharmaceuticals (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions